ARQT Arcutis Biotherapeutics: Quarterly Sales Growth

Corporate company logo of Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics (ARQT) develops unique non-steroidal dermatitis treatments, allowing the brand to maintain flexible pricing power. On GURU.Markets, the quarterly revenue growth rate confirms this strategy, where the value 45.60 captures this metric. Prospects rely on the innovative drug ZORYVE for treating psoriasis and a streamlined distribution system via certified partners, ensuring stable access to pharmacy chains.

Arcutis (ARQT) - Sales Change QoQ from 07/04/2022 to 11/20/2026

Metric breakdowns and analytics for Arcutis Biotherapeutics Inc (ARQT)

- stock price and consensus target price:
- company stock capitalization data:
- cash and cash flow metrics:
General company analysis:Arcutis Biotherapeutics (ARQT)
Mass-produced product of Arcutis

The commercialization dynamics of non-steroidal dermatological products from Arcutis Biotherapeutics (ARQT) are directly reflected in the quarterly revenue growth statistics. This indicator calculates the relative rate of change in revenue between reporting periods, allowing investors to assess the pace of business expansion and the fundamental stability of assets by comparing actual operational acceleration with market expectations.